Release of more study results

Panion Animal Health AB develops a new gene therapy treatment for epilepsy in dogs. The clinical phase of a safety study in dogs under the lead of associate professor David Woldbye at the University of Copenhagen was recently finalized, as reported on August 30, 2018.

More study results are now available from the blood samples of the dogs, specifically relating to the presence of the vector in the time after treatment. The testing was performed in a professional GLP testing facility in Germany with very high quality and using updated, sensitive methods.

"The results confirm our expectations and the sampling period was in the right time frame" says Anja Holm, CEO of Panion. "We find that this part of the study is successful and of good quality. It is also an important and reassuring result, that there was no spread of vector between the dogs, i.e. from treated to control dogs in contact, at the levels tested in this study model. This builds part of the picture for a new gene therapy treatment and we will discuss the results with the authorities. It is necessary to get a good indication of the overall registration requirements in the light of our data, before we can finalize the development plan for our intended new product."

Panion Animal Health AB will meet with the US authorities in the FDA Presubmission meeting in October 2018. More information will be released about additional study results as the analyses will be finalized and reported in the coming months.

This press release contains information which Panion Animal Health AB is obliged to publish according to the EU market abuse regulation (MAR). This information was submitted by Panion's CEO, Anja E. H. Holm, for publication on September 21 2018.


Anja E. H. Holm, CEO
+ 45-22 94 66 00

Bolaget ska utveckla och kommersialisera genterapi för behandling av epilepsiliknande tillstånd hos hundar och andra djur, samt utveckla och kommersialisera andra veterinärmedicinska produkter och nya behandlingsformer som kan ge sjuka djur bättre livskvalitet.
Panion will develop and commercialize a gene therapy treatment for dogs with drug refractory epilepsy, and other new animal health products and treatments that improve the quality of life for animals suffering from chronic diseases.

Nerladdningsbara filer

Panion attracts attention from animal health media

Panion is attracting interest from the agribusiness intelligence and animal health media Animal Pharm, where journalist Sian Lazell yesterday, of January 2019, noted the news on financing of the development program from Panion: "Panion secures extra funding to back R&D. The financing round was carried out through the issuance of notes with warrants attached to Yorkville Advisors Global, that have a principal amount of SEK 100,000 each.

Panion kallar på en andra tranche av konvertibler om 2 miljoner kronor

Panion Animal Health AB ("Panion") kallar på en andra tranche från den investeringsfond som förvaltas av Yorkville Advisors Global ("Yorkville").

Panion draws down a second tranche of convertibles of SEK 2 million

Panion Animal Health AB ("Panion") draws down a second tranche from the investment fund managed by Yorkville Advisors Global ("Yorkville").  

The rights issue in Panion Animal Health AB has been registered by the Swedish Companies Registration Office

The rights issue which was decided by the Board of Panion Animal Health AB, with the authorization of the Annual General Meeting of 29 May 2018, has now been registered by the Swedish Companies Registration Office. Shares and share capital after the registration by the Swedish Companies Registration Office amount to SEK 1,137,110.723254 divided into 24,399,487 shares.

Följ oss

Om beQuoted

beQuoted publicerar nyheter, analyser och pressmeddelanden för investerare och journalister. Viktiga företagshändelser bevakas av vår egen nyhetsredaktion och vidaredistribueras i ledande finansiella medier.

Vi uppdaterar även nyhetsrum, Investor Relations och IR-webbplatser för företag som vill utveckla sina relationer med finansmarknaden.

Kontakta oss

beQuoted AB
Sturegatan 32
114 36 Stockholm

08-692 21 90

Kontakta oss

Vill du veta mer om beQuoted och våra tjänster så fyll i nedanstånde uppgifter och tryck skicka.

En av våra rådgivare kontaktar dig inom kort.

Namn: Telefon: E-postadress: Meddelande: